Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeted therapy: An elusive cancer target.

Literature DB >> 27626779

Targeted therapy: An elusive cancer target.

Carolyn Brown.

Abstract

Entities: Disease

Mesh：

Substances：
Angiogenesis Inhibitors

Year: 2016 PMID： 27626779 DOI： 10.1038/537S106a

Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962

× No keyword cloud information.

4 in total

1. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors: Toni K Choueiri; Bernard Escudier; Thomas Powles; Paul N Mainwaring; Brian I Rini; Frede Donskov; Hans Hammers; Thomas E Hutson; Jae-Lyun Lee; Katriina Peltola; Bruce J Roth; Georg A Bjarnason; Lajos Géczi; Bhumsuk Keam; Pablo Maroto; Daniel Y C Heng; Manuela Schmidinger; Philip W Kantoff; Anne Borgman-Hagey; Colin Hessel; Christian Scheffold; Gisela M Schwab; Nizar M Tannir; Robert J Motzer
Journal: N Engl J Med Date: 2015-09-25 Impact factor: 91.245

2. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.

Authors: Robert J Motzer; Thomas E Hutson; Hilary Glen; M Dror Michaelson; Ana Molina; Timothy Eisen; Jacek Jassem; Jakub Zolnierek; Jose Pablo Maroto; Begoña Mellado; Bohuslav Melichar; Jiri Tomasek; Alton Kremer; Han-Joo Kim; Karen Wood; Corina Dutcus; James Larkin
Journal: Lancet Oncol Date: 2015-10-22 Impact factor: 41.316

3. Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Authors: Robert J Motzer; Thomas E Hutson; David Cella; James Reeves; Robert Hawkins; Jun Guo; Paul Nathan; Michael Staehler; Paul de Souza; Jaime R Merchan; Ekaterini Boleti; Kate Fife; Jie Jin; Robert Jones; Hirotsugu Uemura; Ugo De Giorgi; Ulrika Harmenberg; Jinwan Wang; Cora N Sternberg; Keith Deen; Lauren McCann; Michelle D Hackshaw; Rocco Crescenzo; Lini N Pandite; Toni K Choueiri
Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245

4. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

Authors: Naomi B Haas; Judith Manola; Robert G Uzzo; Keith T Flaherty; Christopher G Wood; Christopher Kane; Michael Jewett; Janice P Dutcher; Michael B Atkins; Michael Pins; George Wilding; David Cella; Lynne Wagner; Surena Matin; Timothy M Kuzel; Wade J Sexton; Yu-Ning Wong; Toni K Choueiri; Roberto Pili; Igor Puzanov; Manish Kohli; Walter Stadler; Michael Carducci; Robert Coomes; Robert S DiPaola
Journal: Lancet Date: 2016-03-09 Impact factor: 79.321

4 in total

20 in total

1. Quantitative Size-Based Analysis of Tumor Spheroids and Responses to Therapeutics.

Authors: Pradip Shahi Thakuri; Megha Gupta; Madison Plaster; Hossein Tavana
Journal: Assay Drug Dev Technol Date: 2019-04 Impact factor: 1.738

Review 2. Marketed drugs used for the management of hypercholesterolemia as anticancer armament.

Authors: Panagiota Papanagnou; Theodora Stivarou; Ioannis Papageorgiou; Georgios E Papadopoulos; Anastasios Pappas
Journal: Onco Targets Ther Date: 2017-09-08 Impact factor: 4.147

Review 3. Reactive Oxygen Species-Mediated Mechanisms of Action of Targeted Cancer Therapy.

Authors: Hanna-Riikka Teppo; Ylermi Soini; Peeter Karihtala
Journal: Oxid Med Cell Longev Date: 2017-06-18 Impact factor: 6.543

Review 4. Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy.

Authors: Marianela Robainas; Rafael Otano; Stephen Bueno; Sihem Ait-Oudhia
Journal: Onco Targets Ther Date: 2017-03-23 Impact factor: 4.147

5. Polymer-Based Nanocarriers for Co-Delivery and Combination of Diverse Therapies against Cancers.

Authors: Guowen Yan; Aihua Li; Aitang Zhang; Yong Sun; Jingquan Liu
Journal: Nanomaterials (Basel) Date: 2018-02-03 Impact factor: 5.076

6. KAT3B-p300 and H3AcK18/H3AcK14 levels are prognostic markers for kidney ccRCC tumor aggressiveness and target of KAT inhibitor CPTH2.

Authors: Elisa Cocco; Manuela Leo; Claudia Canzonetta; Serena Di Vito; Antonello Mai; Dante Rotili; Arianna Di Napoli; Andrea Vecchione; Cosimo De Nunzio; Patrizia Filetici; Antonella Stoppacciaro
Journal: Clin Epigenetics Date: 2018-04-04 Impact factor: 6.551

7. In Vivo Optofluidic Switch for Controlling Blood Microflow.

Authors: Xiaoshuai Liu; Qing Gao; Yao Zhang; Yuchao Li; Baojun Li
Journal: Adv Sci (Weinh) Date: 2020-06-09 Impact factor: 16.806

Review 8. Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients.

Authors: Matthias Totzeck; Raluca Ileana Mincu; Tienush Rassaf
Journal: J Am Heart Assoc Date: 2017-08-10 Impact factor: 5.501

9. LncRNA LOC653786 promotes growth of RCC cells via upregulating FOXM1.

Authors: Fan Yang; Qingjian Wu; Yan Zhang; Haojun Xiong; Xinzhe Li; Bo Li; Wei Xie; Le Zhang; Min Xu; Kebin Zhang; Fengtian He
Journal: Oncotarget Date: 2018-01-08

10. Novel therapeutic features of disulfiram against hepatocellular carcinoma cells with inhibitory effects on a disintegrin and metalloproteinase 10.

Authors: Kaku Goto; Jun Arai; Anthony Stephanou; Naoya Kato
Journal: Oncotarget Date: 2018-04-10